biotech news

Valneva Announces Launch of Approximately $40 Million in a Proposed Global Offering of American Depositary Shares and Ordinary Shares

Saint Herblain (France), September 28, 2022 - Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) (the "Company"), a specialty vaccine company, today announced its intention to issue and sell, subject to … [Read more...] about Valneva Announces Launch of Approximately $40 Million in a Proposed Global Offering of American Depositary Shares and Ordinary Shares

Saint-Herblain (France), 28 septembre 2022 - Valneva SE (Nasdaq : VALN ; Euronext Paris : VLA), soci?t? sp?cialis?e dans les vaccins, annonce aujourd'hui, sous r?serve des conditions de march?, son … [Read more...] about Valneva annonce le lancement d’un projet d’offre globale d’environ $40 millions d’American Depositary Shares et d’actions ordinaires

Financial highlights Cash and cash equivalents totaled EUR209 million as of June 30, 2022Net loss totaled EUR10 million for the first half 2022Developments in our programs Patient enrollment for the … [Read more...] about GENFIT Reports First Half-Year 2022 Financial Results and Provides Corporate Update

R?sultats financiers Tr?sorerie de cl?ture de 209 millions d'euros au 30 juin 2022 R?sultat net n?gatif de 10 millions d'euros au premier semestre 2022Avanc?es des programmes Recrutement pour la … [Read more...] about GENFIT : R?sultats financiers du premier semestre 2022 et point sur les activit?s de la Soci?t?

WARRINGTON, Pa., Sept. 28, 2022 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology company focused on advancing multiple late-stage interventions for acute … [Read more...] about Windtree Therapeutics Announces Positive Istaroxime Phase 2 Study in Early Cardiogenic Shock (SEISMiC) Published in the European Journal of Heart Failure

WVE-006 is the most advanced candidate for AATD designed to restore functional wild-type AAT protein and reduce Z-AAT protein aggregation with potential for disease modification in both lung and liver … [Read more...] about Wave Life Sciences Highlights Therapeutic Potential for WVE-006 for Alpha-1 Antitrypsin Deficiency and Progress Bringing RNA Editing to the Clinic During Analyst and Investor Event

PHILOGEN S.p.A. BOARD OF DIRECTORS APPROVES HALF-YEAR FINANCIAL REPORT AS OF JUNE 30, 2022 (Courtesy English Translation) Revenues from contracts with customers amounting to EUR18,085 thousand … [Read more...] about Board of Directors Approves Half-Year Financial Report as of June 30, 2022

Appointment of Stuart Loesch as President Leverages His Strong Leadership Abilities and Extensive Expertise in Allergy and Pharmaceutical Development Appointment of William Berger, MD, MBA as Head of … [Read more...] about Intrommune Expands and Strengthens Senior Leadership Team

SALT LAKE CITY, Sept. 28, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced results from a nationwide survey it conducted … [Read more...] about Family Cancer History Still a Mystery to Many Women, Myriad Genetics Survey Finds

Centralized Procedure Allows for Submission of a Single Marketing Application to the European Medicines Agency that, if Approved, Would Allow D-PLEX100 to be Marketed in All EU Member States D-PLEX100 … [Read more...] about PolyPid Announces Eligibility for European Medicines Agency Centralized Procedure for D-PLEX??? for the Prevention of Surgical Site Infections in Abdominal Surgery